Cline Scientific starts tests on live patient material with clinical researchers at Swedish hospital

Cline Scientific have begun to utilize live tumor cells directly from cancer patients to develop and test their diagnostic prototype for metastasizing cancers to bring this technology to market.

The tumor cells originate from biopsies taken from patients with benign or metastatic tumors. Cline’s prototype has shown promising results in differentiating metastatic from benign tumor cells.

Testing on live patient material is a necessary technical step to test how cells from patient biopsies behave before the company is able to initiate clinical relevance studies of the cancer diagnostics tool. Cline has started a collaboration with clinical researchers at a Swedish hospital and now has access to cutting edge cell handling procedures which allows for safe transport of biopsies.

Following the start of testing on live patient material, Cline has expanded their cell-lab facility and the new department will solemnly be utilized for clinical work. Cline will now focus all efforts to advance the product development in a clinical setting to get relevant patient data.

” We are finally at the point where all four areas of relevance has come together that are necessary to initiate the clinical phase of the development of this project. Material and input from the clinic, a fully equipped cell lab with the right expertise, a way to handle the biopsy material, and a robust prototype for the actual analysis. All these factors have to converge inorder to start the evaluation of our product in a clinical setting, now we have arrived at that point! We are very encouraged to move forward with this project and aim to finalize these tests during 2020.” Patrik Sundh, CEO